Cara Therapeutics, Inc. (CARA): Price and Financial Metrics

CARA POWR Grades

• CARA scores best on the Value dimension, with a Value rank ahead of 54.47% of US stocks.
• CARA's strongest trending metric is Stability; it's been moving up over the last 179 days.
• CARA's current lowest rank is in the Sentiment metric (where it is better than 12.18% of US stocks).

CARA Stock Summary

• With a one year PEG ratio of 0.59, Cara Therapeutics Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 3.39% of US stocks.
• Over the past twelve months, CARA has reported earnings growth of -1,245.76%, putting it ahead of merely 1.7% of US stocks in our set.
• As for revenue growth, note that CARA's revenue has grown -82.95% over the past 12 months; that beats the revenue growth of only 1.32% of US companies in our set.
• If you're looking for stocks that are quantitatively similar to Cara Therapeutics Inc, a group of peers worth examining would be MORF, NKTR, CCCC, CUE, and ACET.
• CARA's SEC filings can be seen here. And to visit Cara Therapeutics Inc's official web site, go to www.caratherapeutics.com.

CARA Valuation Summary

• In comparison to the median Healthcare stock, CARA's price/earnings ratio is 159.18% higher, now standing at 94.6.
• CARA's EV/EBIT ratio has moved up 162.9 over the prior 92 months.
• CARA's price/sales ratio has moved down 17.2 over the prior 92 months.

Below are key valuation metrics over time for CARA.

CARA Growth Metrics

Its year over year price growth rate is now at -21.55%.
• The 4 year cash and equivalents growth rate now stands at 85.75%.
• Its 3 year price growth rate is now at 241.11%.

CARA's revenue has moved up $22,117,000 over the prior 52 months.

The table below shows CARA's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-12-31	23.028	-60.087	-88.441
2021-09-30	134.296	23.246	23.85
2021-06-30	123.29	15.742	8.354
2021-03-31	128.924	9.095	14.031
2020-12-31	135.082	-5.487	8.41
2020-09-30	27.504	-118.741	-99.11

CARA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• CARA has a Quality Grade of C, ranking ahead of 32.88% of graded US stocks.
• CARA's asset turnover comes in at 0.554 -- ranking 69th of 682 Pharmaceutical Products stocks.
• APLS, FENC, and FSTX are the stocks whose asset turnover ratios are most correlated with CARA.

The table below shows CARA's key quality metrics over time.